Abstracts

Darunavir(DRV)/r-Based PEP Versus Standard of Care (SOC) – the Randomized PEPDar Study

Background: Post exposure prophylaxis (PEP) for 4 weeks is state-of-the-art following exposure to HIV with high risk of transmission. None of the recommended regimens has been studied in prospective randomized studies in this indication so far, discontinuations rates due to side effects are high. Darunavir/r has a favorable safety profile and high antiviral potency. It…

Uptake of Treatment as Prevention and Continuum of Care among Men who have Sex with Men in Nigeria

Background: Evidence has shown that treatment of HIV infection with antiretroviral therapy (ART) prevents heterosexual transmission of HIV to an uninfected partner. However, the “real world” application of this strategy to key populations such as men who have sex with men (MSM) has been limited. We report preliminary findings on acceptability of a treatment as…

Cost Effectiveness of Antiretrovirals in HIV Control in Rural Zambia: A Stochastic League Approach

Background: Earlier ART initiation and pre-exposure prophylaxis (PrEP) have both been demonstrated to effectively prevent new HIV infections. There is, however, limited funding available for HIV prevention. Choices must therefore be made when deciding on the optimal prevention strategy. The aim of this study was to compare the epidemiological impact, cost effectiveness and economic affordability…

First-Line RAL + DRV/r is Non-Inferior to TDF/FTC +DRV/r: The NEAT001/ANRS143 Randomised Trial

Background: NEAT001/ANRS143 is a randomised, open-label, non-inferiority study comparing efficacy, safety and tolerability of darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) in antiretroviral (ARV) treatment-naive HIV-infected adults. We present the final results from the trial, which involved 78 clinical sites from 15 countries. Methodology: Primary outcome was time to first occurrence of failure…

Efficacy and Tolerability of Atazanavir Raltegravir or Darunavir With FTC/Tenofovir: ACTG 5257

Background: Non-nucleoside reverse transcriptase inhibitor (NNRTI) based antiretroviral therapy (ART) is not suitable for all HIV-infected persons. A5257, a randomized, open label trial, was designed to provide rigorous evaluation of virologic efficacy and tolerability of three NNRTI sparing preferred initial ART regimens. Methodology: ART naive persons ≥ age 18 years with HIV-1 RNA (VL) >1000…

Attachment Inhibitor Prodrug BMS-663068 in ARV-Experienced Subjects: Week 24 Analysis

Background: New antiretrovirals (ARVs) are needed for treatment-experienced (TE) HIV+ patients due to the development of resistance and the long-term safety and tolerability issues observed with existing agents. BMS-663068 is a prodrug of BMS-626529, an attachment inhibitor that binds directly to HIV-1 gp120, preventing the initial interaction between virus and host cell. This study is…

Sensitive Screening Reveals Widespread Underestimation of Transmitted HIV Drug Resistance

Background: Our previous studies using sensitive testing to better assess transmitted HIV drug resistance were limited to a few large urban areas. Here we applied sensitive resistance screening on a population drawn from broader geographic regions and population densities in the United States. Methodology: We used validated allele-specific PCR assays to screen 1070 de-identified plasma…

Transmitted HIV-1 Drug Resistance Between Partner-Pairs

Background: Population-based studies suggest that drug resistant HIV-1 is less likely to be transmitted than drug-susceptible viruses. We aimed to evaluate the likelihood of transmission of HIV-1 drug resistance between confirmed partner-pairs. Methodology: Persons with primary HIV-1 infection have enrolled in an observational cohort at the University of Washington Primary Infection Clinic (PIC) since 1992.…

Silent Mutations in HIV-1 Subtype B Reverse Transcriptase Selected by ART Restore Viral Fitness

Background: Most mutations selected during antiretroviral therapy (ART) are non-synonymous (i.e. result in an amino acid change). However, silent mutations, K65K and K66K, in HIV-1 reverse transcriptase (RT) occur in over 35% of highly experienced patients and are among the most commonly selected mutations in subtype B strains. K65K/K66K are associated with thymidine analogue mutations…